We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Programme Details Sample Clauses

Programme Details. In consideration of the pre-payment by Corgentech of the purchase price of the Products in accordance with the schedule set forth in Section 3 below: (a) Avecia shall use its reasonable commercial efforts to manufacture the Products, in accordance with the production schedule and specific requirements detailed in Part B of Schedule 1. (b) In the event a batch of Product produced by Avecia does not meet the relevant Specification, the parties shall decide whether the Specification may be adjusted in order for the batch to meet the Specification. If the parties agree that the relevant Specification can be amended, such agreement shall be recorded in writing. If a batch of Product produced by Avecia does not meet the relevant Specification, Avecia shall use its reasonable commercial efforts to replace such batch, from production at Avecia’s Grangemouth or Milford, Massachusetts facility, at no cost to Corgentech, within six months after notice from Corgentech of such failure to meet the relevant Specification. If a batch of Product meets the relevant Specification (whether amended under this paragraph or otherwise) Avecia shall deliver to Corgentech, a sample of each non-GMP batch and each batch of Product produced in accordance with GMP. (c) Avecia shall package and deliver the Products in accordance with Section 4 below. (d) The Programme shall be deemed to be complete when all batches of the Products produced under the Programme have been delivered to Corgentech or its designee under Section 4.
Sample 1
Programme Details. The Programme has three stages and shall be conducted as follows: (a) Stage 1 - The Feasibility Study (i) The Feasibility Study commenced on the Commencement Date. (ii) The Feasibility Study shall be deemed to be complete when Avecia has notified Insmed that it has completed the Feasibility Study and delivered to Insmed the material and documentation set out in the Milestones Appendix in respect of the Feasibility Study, and such performance is mutually agreed by the JPMC. (b) Stage 2 - The Development Programme. (i) Following completion of the Feasibility Study, the parties shall jointly determine whether the Feasibility Study has been successful and indicates that there is scope for further development of the Process. (ii) If the parties agree that the Feasibility Study has been successful, Avecia shall commence the Development Programme, including the production of the Cell Banks in accordance with the requirements set out therefor in Schedule 8. (iii) Subject to Clause 2.2(b)(iv), the Development Programme shall be complete when Avecia notifies Insmed that it has completed manufacture of the Product in accordance with the Specification at [REDACTED] litre scale, tested such manufactured Product, and provided Insmed with (i) analytical data in a form to be agreed and (ii) revised cost models for manufacture of the Product at large scale, and such performance is mutually agreed by the JPMC. (iv) The parties anticipate that further work will need to be carried out during the Development Programme, the exact nature of which is not certain at the date of this Agreement. Such further work shall be carried out subject to agreement under Clause 2.5. (c) Stage 3 - GMP Stage (i) Avecia shall commence the GMP Stage following completion of the Development Programme. (ii) The GMP Stage shall be complete when Avecia notifies Insmed that it has completed manufacture of the End Product in accordance with the Specification in its Advanced Biologics Centre at [REDACTED] litre scale, tested such manufactured End Product, delivered the End Product so manufactured in accordance with Clause 4 and provided Insmed with (i) a certificate of analysis showing that the End Product manufactured during the GMP Stage accords to the Specification and (ii) a batch production record on such activities, and such performance is mutually agreed by the JPMC. (iii) The Programme shall be complete when the GMP Stage has been completed, and the parties have agreed whether the Master Cell Bank...
Sample 1
Programme Details. 1.1 Name of Programme In Pursuit (IP) year 1 1.2 DHET registration number of Learnership 1.3 Commencement date of agreement 1 February 2020 1.4 Termination date of agreement 30 November 2020 1.5 Occupation that this programme is related to (as per organising framework of occupations (OFO): 1.6 Name of Qualification Further Education and Training Certificate: Generic Management (NQF Level 4) 1.7 SAQA qualification ID number 57712
Sample 1
Programme Details. Avecia shall use reasonable commercial endeavours to carry out the Programme in accordance with the Scope Statement, the QA Agreement, the Programme Management Plan and the Programme Timeline.
Sample 1
Programme Details. Complete either A or B, as applicable. Language of delivery and assessment: If not English, describe the arrangements for monitoring and reviewing the articulation, and how the English language competence of the students will be determined for entry onto the Brookes programme. Other national qualifications frameworks, as relevant.
Sample 1
Programme Details. Complete section A and then either section B or section C Section A Manager / Team Leader name: Telephone number: Email: Total no of learners: Total no of learner hours (if relevant)
Sample 1

Related to Programme Details

  • Notice Details Party A: Banque AIG, London Branch Address: {circle} Facsimile No.: {circle} Attention: {circle} Party B: Permanent Financing (No. 4) PLC Address: Xxxxxxxxx Xxxxx Xxxxxxxxx Xxxx Xxxxxx XX0X 0XX Facsimile Number: 020 7566 0975 Attention: The Secretary With a copy to: (i) the Security Trustee:

  • Payment Details payments due to the School by Parents under this agreement or from time to time due to the School by Parents must be made to the School paid by BACS to Widford Lodge School Ltd, Account number: 00000000, Sort Code: 60-05-13. The Parents should use the Child’s name as reference when making any payment.

  • Contact details 9.1. Any notice, demand, offer or other written instrument required or permitted to be given pursuant to this Standard Transmission Agreement and to the Access Code for Transmission shall be sent to the contact persons mentioned in the contact details sheet as published on the Fluxys Belgium website. The duly filled contact details sheet will be added to attachment 1 of this Agreement. 9.2. Each Party may change these contact detail to which notice shall be sent, or specify one additional address to which copies of notices shall be sent, in accordance with the provisions of this Standard Transmission Agreement.

  • Account Details (a) Account for delivery of Shares to Dealer: To be furnished (b) Account for delivery of Shares to Counterparty: To be furnished (c) Account for payments to Counterparty: To be advised under separate cover or telephone confirmed prior to each Settlement Date (d) Account for payments to Dealer: To be advised under separate cover or telephone confirmed prior to each Settlement Date

  • Invoice Detail All charges for services rendered or for reimbursement of expenses authorized by Department pursuant to the Grant Work Plan shall be submitted to Department in sufficient detail for a proper pre-audit and post-audit to be performed. The Grantee shall only invoice Department for deliverables that are completed in accordance with the Grant Work Plan.

  • Product Support Not applicable

  • Technical Support Services 2.1 The technical support services (the "Services"): Party A agrees to provide to Party B the relevant services requested by Party B, which are specified in Exhibit 1 attached hereto ("Exhibit 1").

  • Technical Support State Street will provide technical support to assist the Fund in using the System and the Data Access Services. The total amount of technical support provided by State Street shall not exceed 10 resource days per year. State Street shall provide such additional technical support as is expressly set forth in the fee schedule in effect from time to time between the parties (the “Fee Schedule”). Technical support, including during installation and testing, is subject to the fees and other terms set forth in the Fee Schedule.

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order. (b) The technical evaluation committee may call the responsive bidders for discussion or presentation to facilitate and assess their understanding of the scope of work and its execution. However, the committee shall have sole discretion to call for discussion / presentation. (c) Financial bids of only those bidders who qualify the technical criteria will be opened provided all other requirements are fulfilled. (d) AIIMS Jodhpur shall have right to accept or reject any or all tenders without assigning any reasons thereof.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Most Referenced Clauses

Most Referenced Definitions